Our website is set to 'allow cookies' to give you the best experience without telling us who you are. Please continue if you consent to this, or click below to change your settings:
Find out more about our cookies policy
(+1) 617 896 0213
info@sagentia.com
View all hot topics
1/4
It was announced Monday morning that Life Technologies has been purchased by Thermo Fisher for $13.6bn. Whist this acquisition is not totally unexpected, it is Life Tech’s DNA sequencing technology - Ion Torrent - that is of particular interest in this case.
Last week the European Organization for Nuclear Research, or CERN, announced that their research endeavours ‘strongly indicate’ that they have solid evidence of the Higgs Boson particle. What is the value of this discovery beyond academic research?
Management Forum’s Injectable Drug Delivery conference in London last week highlighted the importance of parenteral drug delivery both now and in the future.
The horse meat scandal has caused a media storm, and provided more than a few jokes around the topic, but apart from the mislabelling of goods and misleading the public about what they were eating, is there any danger? And how can a similar scandal be prevented in the future?
Which skin cream do I buy? How often should I apply it? These and other personal care questions are increasingly being answered on what seems like a personalised one-to-one basis. But how could this be possible when a skin or haircare product is bought by 10’s of millions of consumers every year?
The BBC has recently reported on an initiative by the Payments Council to launch a service enabling money transfers by mobile phone in 2014. Having developed the M-Pesa mobile payment system for use in the developing world, Sagentia reflects on the challenges of creating a similar system for the UK.
Following reports that Roche Holding AG may have agreed to buy Illumina, Inc., the US maker of DNA sequencing equipment, Sagentia's Diagnostics Instrumentation Consultant, Nick Rolllings, comments on the impact of the deal on the DNA sequencing sector.
Sagentia's Head of Intellectual Property Services, Mark Cohen, comments on the advent of a new european single patent system, as reported in the Financial Times.
Join us at the HBA Global Expo in New York this June. As part of the event, Sagentia’s Peter Luebcke will be speaking on the topic of the trend towards DIY consumer products.
The sixth IPBC is taking pace at The Westin Waterfront Hotel in Boston from 9th to 11th June. The IPBC has established itself as the world’s principal forum for senior thought leaders who specialise in the business of IP to come together to discuss cutting-edge issues around IP value creation.
MIT Technology Review and Sagentia review the 10 Breakthrough Technologies for 2013 that will have the greatest impact on the shape of innovation
Sagentia Inc., a global technology and product development company, announced that it has completed initial alpha prototype development of the RESOLUTIONTM Microbial Genotyping System that it is developing for PathoGenetix Inc.
In an article published in HAPPI magazine Dr. Peter Luebcke, Senior Personal Care Consultant at Sagentia, explores the challenges faced by cosmetic companies when constantly pushing the boundaries of the cosmetic definition to claim one-upmanship efficacy of their products.
As IVD devices move into the hands of untrained consumers, user-centered design is critical. Sagentia explores how usability is key to understanding these new environments, published in MDDI.
Experts in complex science & technology Multidisciplinary, cross sector team approach Excel at meeting aggressive timescales Customer friendly approach to IP Accreditation to ISO9001:2008 and ISO13485:2003 What our clients say: "We have worked with Sagentia on a number of issues. The reason in every case is their ability to deliver innovative engineering and then deliver on execution."
Keep track of site upates using our RSS feeds, click a link below to view the feed.